Drugs / CX-904
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05387265 | May 2022 → Jun 2025 | cancer | CytomX Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX-904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387265 ↗ |
| Target | EGFR | “against Epidermal Growth Factor Receptor (EGFR) and CD3” NCT05387265 ↗ |